Literature DB >> 19089920

Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3.

Mark E Scott1, Yifei Ma, Lili Kuzmich, Anna-Barbara Moscicki.   

Abstract

Cervical mucosal expression of cytokines involved in mediating cellular immunity is believed to influence the persistence of human papillomavirus (HPV) infection, a necessary prerequisite for the development of cervical intraepithelial neoplasia (CIN). Additionally, regulatory T (Treg) cells are increasingly understood to be important modulators of cellular immunity. Using quantitative RT-PCR, we measured, in cross-sectional design, the cervical mRNA expression of IFN-gamma, IL-10, and IL-12, as well as the Treg transcription factor Forkhead box P3 (Foxp3), in a cohort of young women representing CIN 1, 2, and 3, as well as benign histology. Higher levels of IFN-gamma and IL-10 were significantly (p <or= 0.05) associated with decreased odds of having high-grade cervical disease (CIN 2 or 3) in multivariate logistic regression models. In contrast, higher levels of mucosal Foxp3 expression were associated with increased odds of having CIN 2 or 3 (p = 0.004). In a multivariate model including cervical infection with HPV16 and/or another high-risk HPV type, Foxp3 remained higher in the CIN 2/3 group, but the difference was notably less significant (p = 0.05). These findings support a model in which diminished cellular immunity in the cervical mucosa and mucosal enrichment of Treg cells both contribute to the development of high-grade lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19089920      PMCID: PMC2696072          DOI: 10.1002/ijc.24117

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

Review 1.  Biology and evolution of cervical squamous intraepithelial lesions: a hypothesis with diagnostic prognostic implications.

Authors:  Kumarasen Cooper; Mark Evans; Sharon Mount
Journal:  Adv Anat Pathol       Date:  2003-07       Impact factor: 3.875

2.  Regression of low-grade squamous intra-epithelial lesions in young women.

Authors:  Anna-Barbara Moscicki; Stephen Shiboski; Nancy K Hills; Kimberly J Powell; Naomi Jay; Evelyn N Hanson; Susanna Miller; K Lisa Canjura-Clayton; Sepidah Farhat; Jeanette M Broering; Teresa M Darragh
Journal:  Lancet       Date:  2004 Nov 6-12       Impact factor: 79.321

Review 3.  Rethinking the molecular definition of regulatory T cells.

Authors:  Shohei Hori
Journal:  Eur J Immunol       Date:  2008-04       Impact factor: 5.532

4.  Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer.

Authors:  A M El-Sherif; R Seth; P J Tighe; D Jenkins
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

5.  Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix.

Authors:  T D de Gruijl; H J Bontkes; A J van den Muysenberg; J W van Oostveen; M J Stukart; R H Verheijen; N van der Vange; P J Snijders; C J Meijer; J M Walboomers; R J Scheper
Journal:  Eur J Cancer       Date:  1999-03       Impact factor: 9.162

6.  Distribution of lymphocytes and adhesion molecules in human cervix and vagina.

Authors:  E L Johansson; A Rudin; L Wassén; J Holmgren
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

7.  Th1 cytokine patterns in cervical human papillomavirus infection.

Authors:  M Scott; D P Stites; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

8.  Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.

Authors:  M Nakagawa; D P Stites; S Farhat; J R Sisler; B Moss; F Kong; A B Moscicki; J M Palefsky
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

9.  Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.

Authors:  Annemieke de Jong; Mariëtte I E van Poelgeest; Jeanette M van der Hulst; Jan Wouter Drijfhout; Gert Jan Fleuren; Cornelis J M Melief; Gemma Kenter; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 10.  Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactors.

Authors:  Philip E Castle; Anna R Giuliano
Journal:  J Natl Cancer Inst Monogr       Date:  2003
View more
  28 in total

Review 1.  Early Defensive Mechanisms against Human Papillomavirus Infection.

Authors:  Andrea Moerman-Herzog; Mayumi Nakagawa
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

2.  Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Authors:  Diane M Da Silva; Carly A Movius; Adam B Raff; Heike E Brand; Joseph G Skeate; Michael K Wong; W Martin Kast
Journal:  Virology       Date:  2014-02-17       Impact factor: 3.616

3.  Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.

Authors:  Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

4.  FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer.

Authors:  Shuang Xu; Mingmei Huangfu; Xueli Jia; Xiaowei Song; Baosheng Sun; Kuang-Hui Lee; Linlin Liu; Shilong Sun
Journal:  Int J Clin Oncol       Date:  2015-02-15       Impact factor: 3.402

5.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

6.  Twelve-Year Trend in the Prevalence of High-Risk Human Papillomavirus Infection Among Rwandan Women Living With HIV.

Authors:  Gad Murenzi; Faustin Kanyabwisha; Anthere Murangwa; Gallican Kubwimana; Leon Mutesa; Robert D Burk; Kathryn Anastos; Philip E Castle
Journal:  J Infect Dis       Date:  2020-06-16       Impact factor: 5.226

7.  Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort.

Authors:  Stina Syrjänen; Paulo Naud; Luis Sarian; Sophie Derchain; Cecilia Roteli-Martins; Adhemar Longatto-Filho; Silvio Tatti; Margherita Branca; Mojca Erzen; L S Hammes; S Costa; Kari Syrjänen
Journal:  Virchows Arch       Date:  2009-11-12       Impact factor: 4.064

8.  Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.

Authors:  Wen Yang; Yan Song; Yun-Long Lu; Jun-Zhong Sun; Hong-Wei Wang
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

9.  The relation of plasmacytoid dendritic cells (pDCs) and regulatory T-cells (Tregs) with HPV persistence in HIV-infected and HIV-uninfected women.

Authors:  Howard D Strickler; Jeffrey Martinson; Seema Desai; Xianhong Xie; Robert D Burk; Kathryn Anastos; L Stewart Massad; Howard Minkoff; Xiaonan Xue; Gypsyamber D'Souza; Alexandra M Levine; Christine Colie; D Heather Watts; Joel M Palefsky; Alan Landay
Journal:  Viral Immunol       Date:  2014-02       Impact factor: 2.257

10.  Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-γ.

Authors:  Lei Wang; Hongying Li; Feng Liang; Yi Hong; Shaowei Jiang; Ling Xiao
Journal:  Med Oncol       Date:  2014-08-09       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.